Flamicort injection 10 mg/ml is indicated for intra-articular or intrabursal administration and for injection into tendon sheaths as adjunctive therapy for short term administration (to tide the patient over an acute episode exacerbation) in: synovitis of osteoarthritis, rheumatoid arthritis, acute or sub-acute bursitis, acute gouty arthritis, epicondylitis, acute nonspecific tenosynovitis, and post-traumatic osteoarthritis.
Intralesional administration of Flamicort injection 10 mg/ml is indicated for treatment of keloids, discoid lupus erythematosus, necrobiosis lipoidica diabeticorum, alopecia areata and localized hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus (neurodermatitis). Flamicort injection 10 mg/ml may be useful in cystic tumors of an aponeurosis or tendon (ganglia).
Triamcinolone 50 mg
Intra-Articular or Intrabursal and for Injection into Tendon Sheaths
- 2.5 to 5 mg for smaller joints
- 5 to 15 mg for larger joints
Single injections into several joints for multiple locus involvement, up to a total of 20 mg or more, have been given without incident. The initial dosage should be maintained or adjusted until a satisfactory response is noted.
Limited to 1.0 mg (0.1 ml) per injection site.
The site of the injection and the volume of the injection should be carefully considered when triamcinolone acetonide is administered. The initial dosage should be maintained or adjusted until a satisfactory response is noted.
The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, Flamicort should be discontinued and the patient transferred to other appropriate therapy. It should be emphasized that dosage requirements are variable and must be individualized on the basis of the disease under treatment and response of the patient. After a favorable response is noted, the proper maintenance dosage must be determined by decreasing the initial drug dosage in small increments at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage.
Included in the situations which may make dosage adjustment necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient’s individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this later situation it may be necessary to increase the dosage of Flamicort for a period of time consistent with patient’s condition. If after long-term therapy the drug is to be stopped, it is recommended that it should be withdrawn gradually rather than abruptly.